These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [The pro-arrhythmic effects of anti-arrhythmia agents]. Haverkamp W; Wichter T; Chen X; Hördt M; Willems S; Rotman B; Hindricks G; Kottkamp H; Borggrefe M; Breithardt G Z Kardiol; 1994; 83 Suppl 5():75-85. PubMed ID: 7846949 [TBL] [Abstract][Full Text] [Related]
44. The utility of serum drug level monitoring during therapy with class III antiarrhythmic agents. Follath F J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S41-3. PubMed ID: 1279308 [TBL] [Abstract][Full Text] [Related]
45. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Hohnloser SH Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415 [TBL] [Abstract][Full Text] [Related]
46. Use of amiodarone in the postmyocardial infarction patient. Ozdil E; Carlson TA; Massumi A Tex Heart Inst J; 1995; 22(1):40-3. PubMed ID: 7787469 [TBL] [Abstract][Full Text] [Related]
47. [Calcium antagonists in treatment of ventricular tachycardia]. Melichercik J; Schöls W; Beyer T; Schweizer M; Brachmann J; Kübler W Z Kardiol; 1996 May; 85(5):319-25. PubMed ID: 8711944 [TBL] [Abstract][Full Text] [Related]
48. Is there a need for new antiarrhythmic drugs? Roden DM Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():13-8. PubMed ID: 8734158 [TBL] [Abstract][Full Text] [Related]
49. Drugs for ventricular arrhythmias in the era of the implantable cardioverter defibrillator. Peters NS Eur Heart J; 1999 Mar; 20(5):321-3. PubMed ID: 10206376 [No Abstract] [Full Text] [Related]
50. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Singh BN Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328 [TBL] [Abstract][Full Text] [Related]
51. Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation. Campbell RW; Furniss SS Am J Cardiol; 1993 Aug; 72(4):80A-85A. PubMed ID: 8346732 [TBL] [Abstract][Full Text] [Related]
52. Na+ channel blockers vs class III antiarrhythmic drugs in treating sustained ventricular tachycardia: reversing and preventing as different electrophysiological mechanisms. Masotti CS; Pierangeli A Panminerva Med; 1999 Dec; 41(4):295-306. PubMed ID: 10705709 [TBL] [Abstract][Full Text] [Related]
53. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. Joseph AP; Ward MR Ann Emerg Med; 2000 Jul; 36(1):1-9. PubMed ID: 10874228 [TBL] [Abstract][Full Text] [Related]
54. [Ventricular cardiac arrhythmias 1992. Summary and perspectives]. Breithardt G; Borggrefe M Z Kardiol; 1992; 81 Suppl 4():163-5. PubMed ID: 1290293 [TBL] [Abstract][Full Text] [Related]
55. [Clinical evaluation of new anti-arrhythmia drugs after the CAST (Cardiac Arrhythmia Suppression Trial) study]. Meinertz T; Zehender M; Hohnloser SH Z Kardiol; 1992; 81 Suppl 4():145-9. PubMed ID: 1290291 [TBL] [Abstract][Full Text] [Related]
60. [Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study]. Niu F; Huang CX; Jiang H; Yang B; Guo WL; Chen YX; Jin CR; Liu ZM Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(2):121-3. PubMed ID: 16620720 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]